Download PDF
Horm Metab Res 2012; 44(07): 555-557
DOI: 10.1055/s-0032-1314804
Short Communication
© Georg Thieme Verlag KG Stuttgart · New York

Evaluation of the BRAHMS KRYPTOR Thyroglobulin “Mini-recovery” Test in Thyroid Healthy Subjects

F. A. Verburg
1   Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany
2   Department of Nuclear Medicine, University of Aachen, Aachen, Germany
,
I. Grelle
1   Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany
,
L. Giovanella
3   Department of Nuclear Medicine and PET Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
,
C. Reiners
1   Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany
› Author Affiliations
Further Information

Publication History

received 28 September 2011

accepted 07 May 2012

Publication Date:
11 June 2012 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of the work was to compare the automated thyroglobulin (Tg) assay on the automated BRAHMS KRYPTOR platform (hTG KRYPTOR) to the established BRAHMS Tg Plus immunoradiometric assay for the measurement of Tg levels and regular Tg recovery rates and to assess a recovery test using a low Tg concentration of 10 μg/l (“mini-recovery”) in samples with a native Tg level of <10 μg/l. Tg levels and recovery rates, as well as the mini-recovery, were determined in 208 serum samples from thyroid-healthy patients using both assays. The reference ranges for the Tg-Plus assay are 2.0–51.0 μg/l for Tg levels and 81.5–108% for recovery rates at 100 μg/l. The reference ranges for hTG KRYPTOR are 2.4–47.8 μg/l for Tg, 83.3–110.4% for a conventional recovery with 80 μg/l in Tg levels ≥10.0 μg/l (n=121) and 94.4–122.9% for the mini-recovery with Tg <10.0 μg/l (n=87). The correlation between the Tg-Plus and hTG KRYPTOR is excellent for Tg (r2=0.95; p<0.001), but not significant for recovery rates. Tg levels determined using the KRYPTOR Tg assay are clinically comparable to the conventional Tg-Plus assay. New features of the KRYPTOR assay such as the ability to perform a “mini-recovery” still require further study before clinical use.

Key words

thyroglobulin antibodies - thyroid cancer - thyroglobulin
 

  • References

  • 1 Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT. J Clin Endocrinol Metab 1998; 83: 1121-1127
    CrossrefPubMed
  • 2 Spencer CA. J Clin Endocrinol Metab 2004; 89: 3702-3704
    CrossrefPubMed
  • 3 Giovanella L, Keller F, Ceriani L, Tozzoli R. Clin Chem Lab Med 2009; 47: 952-954
    CrossrefPubMed
  • 4 Verburg FA, Waschle K, Reiners C, Giovanella L, Lentjes EG. Horm Metab Res 2010; 42: 736-739
    Article in Thieme ConnectPubMed
  • 5 Giovanella L, Toffalori E, Ceriani L, Caputo M, Verburg F. Horm Metab Res 2011; 43: 728-730
    Article in Thieme ConnectPubMed
  • 6 Morgenthaler NG, Froehlich J, Rendl J, Willnich M, Alonso C, Bergmann A, Reiners C. Clin Chem 2002; 48: 1077-1083
    PubMed
  • 7 Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Washington: National Academy of Clinical Biochemistry; 2002
    Google Scholar
  • 8 Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. J Clin Endocrinol Metab 2005; 90: 5566-5575
    CrossrefPubMed
  • 9 Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielny S, Taieb D, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet S, Bussiere F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, Ricard M, Benhamou E. J Clin Endocrinol Metab 2007; 92: 2487-2495
    CrossrefPubMed
  • 10 Erali M, Bigelow RB, Meikle AW. Clin Chem 1996; 42: 766-770
    PubMed